Improved cancer immunotherapy by a CD25-mimobody conferring selectivity to human interleukin-2
出版年份 2016 全文链接
标题
Improved cancer immunotherapy by a CD25-mimobody conferring selectivity to human interleukin-2
作者
关键词
-
出版物
Science Translational Medicine
Volume 8, Issue 367, Pages 367ra166-367ra166
出版商
American Association for the Advancement of Science (AAAS)
发表日期
2016-12-01
DOI
10.1126/scitranslmed.aag3187
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models
- (2016) D. H. Charych et al. CLINICAL CANCER RESEARCH
- Type 2 Interleukin-4 Receptor Signaling in Neutrophils Antagonizes Their Expansion and Migration during Infection and Inflammation
- (2016) Janine Woytschak et al. IMMUNITY
- Selective IL-2 Responsiveness of Regulatory T Cells Through Multiple Intrinsic Mechanisms Supports the Use of Low-Dose IL-2 Therapy in Type 1 Diabetes
- (2015) Aixin Yu et al. DIABETES
- Antibodies to Interleukin-2 Elicit Selective T Cell Subset Potentiation through Distinct Conformational Mechanisms
- (2015) Jamie B. Spangler et al. IMMUNITY
- Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected
- (2015) Douglas Marvel et al. JOURNAL OF CLINICAL INVESTIGATION
- The future of immune checkpoint therapy
- (2015) P. Sharma et al. SCIENCE
- Interleukin-2: Biology, Design and Application
- (2015) Natalia Arenas-Ramirez et al. TRENDS IN IMMUNOLOGY
- The epigenetic modifier EZH2 controls melanoma growth and metastasis through silencing of distinct tumour suppressors
- (2015) Daniel Zingg et al. Nature Communications
- Abstract 486: Tumor-targeted, engineered IL-2 variant (IL-2v)-based immunocytokines for the immunotherapy of cancer.
- (2014) Christian Klein et al. CANCER RESEARCH
- Use of enhanced interleukin-2 formulations for improved immunotherapy against cancer
- (2014) Rodney A Rosalia et al. CURRENT OPINION IN CHEMICAL BIOLOGY
- Regulatory T cells in cancer immunotherapy
- (2014) Hiroyoshi Nishikawa et al. CURRENT OPINION IN IMMUNOLOGY
- IL-7/Anti-IL-7 mAb Complexes Restore T Cell Development and Induce Homeostatic T Cell Expansion without Lymphopenia
- (2014) O. Boyman et al. JOURNAL OF IMMUNOLOGY
- IL-2: The First Effective Immunotherapy for Human Cancer
- (2014) S. A. Rosenberg JOURNAL OF IMMUNOLOGY
- Interleukin-2 at the Crossroads of Effector Responses, Tolerance, and Immunotherapy
- (2013) Wei Liao et al. IMMUNITY
- G-CSF/anti-G-CSF antibody complexes drive the potent recovery and expansion of CD11b+Gr-1+ myeloid cells without compromising CD8+ T cell immune responses
- (2013) Mark P Rubinstein et al. Journal of Hematology & Oncology
- Deciphering the molecular bases of the biological effects of antibodies against Interleukin-2: A versatile platform for fine epitope mapping
- (2012) Gertrudis Rojas et al. IMMUNOBIOLOGY
- Exploiting a natural conformational switch to engineer an interleukin-2 ‘superkine’
- (2012) Aron M. Levin et al. NATURE
- gp100 Peptide Vaccine and Interleukin-2 in Patients with Advanced Melanoma
- (2011) Douglas J. Schwartzentruber et al. NEW ENGLAND JOURNAL OF MEDICINE
- Conditional Regulatory T-Cell Depletion Releases Adaptive Immunity Preventing Carcinogenesis and Suppressing Established Tumor Growth
- (2010) M. W. L. Teng et al. CANCER RESEARCH
- Interleukin-2 Receptor Signaling: At the Interface between Tolerance and Immunity
- (2010) Thomas R. Malek et al. IMMUNITY
- Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
- (2010) Kaori Sakuishi et al. JOURNAL OF EXPERIMENTAL MEDICINE
- IL-2/anti-IL-2 antibody complexes show strong biological activity by avoiding interaction with IL-2 receptor subunit CD25
- (2010) S. Letourneau et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells
- (2010) C. Krieg et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started